

SURGICAL ONCOLOGIST

Applications are solicited for a general surgeon with specific interest in the area of surgical oncology in the Department of Surgery, University of California, Davis.

Candidate must be Board certified or eligible in general surgery and have a minimum of two years research experience substantiated by published articles. The candidate must be a clinically competent surgeon and have teaching ability in the education and training of housestaff and students.


The level of appointment will be commensurate with prior educational and clinical experience and will be at the Assistant, Associate, or full Professor level.

Send curriculum vitae to: F. William Blaisdell, M.D., Chairman, Department of Surgery, 4301 X Street, Room 257, Sacramento, CA 95817.

The University is an affirmative action/equal opportunity employer.

Position open until May 15, 1983.

**This publication
is available in microform.**



University Microfilms International

Please send additional information

Name _____
Institution _____
Street _____
City _____
State _____ Zip _____

300 North Zeeb Road
Dept. P.R.
Ann Arbor, Mi. 48106
U.S.A.

30-32 Mortimer Street
Dept. P.R.
London WIN 7RA
England

Synthetic Analog

Reduce side effects of Adriamycin and Daunomycin

The anthracycline antibiotics—Adriamycin, Daunomycin and Carminomycin—while highly effective against a wide variety of tumors, have been hampered by their toxic side effects. Now, new research suggests that the replacement of the carbohydrate constituent, L-Daunosamine with its C4 epimer, L-Acosamine, will significantly improve these antibiotics.

Adriamycin and Daunomycin analogs, with L-Acosamine carbohydrate moiety, have activity comparable to the parent drugs but not the toxicity to cultured heart cells shown by Adriamycin itself. This is most significant, since cardiotoxicity has halted treatment with Adriamycin while the tumor still is responding to the drug.

Both these sugars, L-Daunosamine and L-Acosamine, now are being prepared synthetically by Pfanstiehl. Moreover, the technology exists to scale up production to large-scale runs.

We invite your inquiry.

MANUFACTURERS OF
Carbohydrates and Derivatives
Pharmaceutical Intermediates
Diagnostic Chemicals and
Research Biochemicals



PFANSTIEHL LABORATORIES, INC.

The Rare Sugar House of the World
1219 Glen Rock Ave., Waukegan IL 60085-0439 Tel: (312) 623-0370

PLEASE SEND ME:

- | | |
|---|---|
| <input type="checkbox"/> Technical Bulletin and Bibliography for Daunomycin and Acosamine | <input type="checkbox"/> Brochure on Pfanstiehl Capability |
| <input type="checkbox"/> New 1982-83 Pfanstiehl Catalog | <input type="checkbox"/> Literature on Carbohydrate reference standards |

Name _____

Title _____

Organization _____

Address _____

City _____ State _____ Zip _____

ACADEMIC PRESS, INC.

CHEMICAL INDUCTION OF CANCER

Volume 3A/STRUCTURAL BASES AND BIOLOGICAL MECHANISMS

JOSEPH ARCOS, YIN-TAK WOO, MARY F. ARGUS
with the collaboration of DAVID Y. LAI

Volume 3A presents extensive discussion of the metabolic aspects and mechanisms of carcinogenic action; physicochemical properties; mutagenicity and teratogenicity; modification of carcinogenicity by endogenous or exogenous factors; environmental formation and occurrence; and potential human exposure.

1982, 752 pp., \$74.50 ISBN: 0-12-059303-3
Subscription price: \$65.00*

ADVANCES IN CANCER RESEARCH

Edited by GEORGE KLEIN
and SIDNEY WEINHOUSE

From the Reviews of Previous Volumes: "The volume should thus take its place, along with its predecessors in the series, as a valuable reference book for all readers interested in cogent aspects of contemporary cancer research."

—THE QUARTERLY REVIEW OF BIOLOGY

Volume 38

CONTENTS: *Benjamin Bonavida*, The SJL/J Spontaneous Reticulum Cell Sarcoma: New Insights in the Fields of Neoantigens, Host-Tumor Interactions, and Regulation of Tumor Growth. *George W. Teebor and Krystyna Frenkel*, The Initiation of DNA Excision Repair. *George W. Sledge, Jr. and William L. McGuire*, Steroid Hormone Receptors in Human Breast Cancer. *Motoo Hozumi*, Fundamentals of Chemotherapy of Myeloid Leukemia by Induction of Leukemia Cell Differentiation. *Eli Kedar and David W. Weiss*, The *in Vitro* Generation of Effector Lymphocytes and Their Employment in Tumor Immunotherapy. *G. Yogeeswaran*, Cell-Surface Glycolipids and Glycoproteins in Malignant Transformation. Index.

May/June 1983, in preparation ISBN: 0-12-006638-6

Volume 37

CONTENTS: *J. Michael Bishop*, Retroviruses and Cancer Genes. *Elisabeth Gateff*, Cancer, Genes, and Development: The *Drosophila* Case. *Arnold J. Levine*, Transformation-Associated Tumor Antigens. *Kari Alitalo and Antti Vaheri*, Pericellular Matrix in Malignant Transformation. *Carmia Borek*, Radiation Oncogenesis in Cell Culture. *Jan Klein and Zoltan A. Nagy*, Mhc Restriction and Ir Genes. *Kenneth Nilsson and George Klein*, Phenotypic and Cytogenetic Characteristics of Human B-Lymphoid Cell Lines and Their Relevance for the Etiology of Burkitt's Lymphoma. *George Klein and Gilbert Lenoir*, Translocations Involving 1g Locus-Carrying Chromosomes: A Model for Genetic Transposition in Carcinogenesis. Index.

1982, 416 pp., \$52.00 ISBN: 0-12-006637-8

METHODS IN CANCER RESEARCH

Volume 20

TUMOR MARKERS

Edited by HARRIS BUSCH and LYNN C. YEOMAN

CONTENTS (Section Headings): Tumor Immunogenicity and Cellular Immunity. Immunochemical Localization and Quantitative Assays. Monoclonal Antibodies and the Tumor Cell Surface.

1982, 400 pp., \$48.50 ISBN: 0-12-147680-4
Subscription price: \$41.50*

Volume 19

CONTENTS (Section Headings): Cell Surface Markers for Neoplasia. Antigen Markers of Tumor Cells and Nuclei. Models and Methods for Diagnosis and Therapy.

1982, 423 pp., \$56.00 ISBN: 0-12-147679-0
Subscription price: \$48.00*

LYMPHOKINES

A FORUM FOR IMMUNOREGULATORY CELL PRODUCTS

Edited by EDGAR PICK

with Advisory Editor: MAURICE LANDY

Volume 8

TENTATIVE PARTIAL CONTENTS: Transfer Factor. IgE-Binding Factors from Rat T Lymphocytes. A Polyclonal B Cell Activating Lymphokine and Its Natural Inhibitor: Possible Role in Antibody Formation and Autoimmune Disease. Lymphokines and Antigen-Specific T Cell Products in Contact Sensitivity. Studies on the Activation of Cytotoxicity and/or Suppressor Activity in Murine Macrophages by Lymphokines, Lipopolysaccharide, and Poly Inosinic-Poly Cytidilic Acid. (Plus eight additional chapters.)

1983, 480 pp., \$57.00 ISBN: 0-12-432008-2

INTERFERON 1982

Volume 4

Editor-in-Chief: ION GRESSER


CONTENTS (Section Headings): How Many Human Interferons Are There? Interferon and Cyclic Nucleotides. Mechanisms of Interferon Action: Biochemical and Genetic Approaches. Can Interferon Induce Disease? The Importance of Having Gamma. Some Thoughts on the Clinical Exploitation of Interferon in Infectious Diseases. Interferon in Ocular Viral Diseases.

1982, 212pp., \$18.50 ISBN: 0-12-302253-3 (Paper)

INTERFERON 1981

Volume 3

1981, 154 pp., \$19.50 ISBN: 0-12-302252-5 (Paper)



A Volume in the **BRISTOL-MYERS CANCER SYMPOSIA Series**

MALIGNANT LYMPHOMAS

ETIOLOGY, IMMUNOLOGY, PATHOLOGY, TREATMENT

Edited by **SAUL A. ROSENBERG**
and **HENRY S. KAPLAN**

This comprehensive volume reviews the etiology, immunology, pathology, and treatment of Hodgkin's Disease and the non-Hodgkin's Lymphomas. The chapters, by leading investigators, discuss • current knowledge of immunologic markers, including monoclonal antibody techniques to understand lymphoid neoplasms • the results of an international comparison of the major pathologic classification systems • a working formulation that permits translation among the classification systems • the latest treatment methods for adults and children with Hodgkin's disease and non-Hodgkin's lymphomas • the long-term complications of therapy and proposed methods to reduce these complications.

1982, 712 pp., \$47.50 ISBN: 0-12-597120-6

Methods in Enzymology

Editors-in-Chief: **SIDNEY P. COLOWICK**
and **NATHAN O. KAPLAN**

Volume 78

INTERFERONS, Part A

Edited by **SIDNEY PESTKA**

CONTENTS (Section Headings): Definition of the Interferons. Induction and Production of Interferons. Viral and Nonviral Inducers of Interferons: Preparation and Characterization. Assay of Interferons. Purification and Characterization of Interferons.

1981, 632 pp., \$59.00 ISBN: 0-12-181978-7

Volume 79

INTERFERONS, Part B

Edited by **SIDNEY PESTKA**

CONTENTS (Section Headings): Techniques for Chromatography and Analysis of Interferons. Isolation and Translation of Interferon Messenger RNA. Methods to Study Mode of Interferon Action: General Methodology and Considerations; Phosphorylation and cAMP in Interferon Action; Synthesis and Assay of (2'—5') Oligoadenylic Acid and Related Events; Effect of Interferon on Protein Synthesis and Other Cellular Processes. Methods to Study Interferon Activity at the Cellular Level. Effects of Interferon on the Cell Membrane, Cell Surface, and Cytoskeleton. Relationships of Interferon to the Immune System. Somatic Cell Genetics of Interferons. Preparation and Assay of Antibodies against Interferons. Cloning of the Interferon Genes and Complementary DNAs.

1982, 677 pp., \$59.00 ISBN: 0-12-181979-5

THE CELL NUCLEUS

Edited by **HARRIS BUSCH**
and **LAWRENCE ROTHBLUM**

FROM THE PREFACE: Volume 10 deals first with the ribosomal RNA genes of *Escherichia coli* (Morgan), algae (Berger and Schweiger), fungi (Bollon), *Dictyostelium* and *Physarum* (Weiner and Emery), and other protozoans (Blackburn). Special features of the rRNA product of *Tetrahymena* are discussed by Cech *et al.* The rDNA of higher organisms is reviewed for insects (Beckingham), sea urchins (Wilson and Stafford), and humans (Wilson.)

Recent developments in the structural analysis of 18 S rRNA and rDNA, the evolutionary patterns of 28 S rDNA, and the mitochondrial rDNA are presented in the chapters by Maden, Gerbi *et al.* and Grant and Lambowitz.

Volumes 11 and 12 of this treatise deal with the 5 S DNA, nucleolar, and other rDNA-containing chromatin as visualized by light and electron microscopy and with the organization of rDNA in chromatin. In addition, the important subjects of transcription and transcriptional control of the rDNA genes, the amplification of rDNA, and the controls of ribosomal genes will be presented.

Volume 10/rDNA, Part A

1982, 448 pp., \$57.00 ISBN: 0-12-147610-3
Subscription price: \$48.50*

Volume 11/rDNA, Part B

1983, 328 pp., \$45.00 ISBN: 0-12-147611-1
Subscription price: \$38.50*

Volume 12/rDNA, Part C

1983, 288pp., \$42.00 ISBN: 0-12-147612-x
Subscription price: \$36.00*

*Subscription prices are valid only on purchase of all volumes before publication of the last volume. Subscription prices are not valid on orders from Australia or New Zealand.

Continuation Orders authorize us to ship and bill each volume in a series, or "Advances" type publication automatically, immediately upon publication. This order will remain in effect until cancelled. Specify the volume number or title with which your order is to begin.

*Send payment with order and save postage and handling.
Prices are in U.S. dollars and are subject to change without notice.*

ACADEMIC PRESS, INC.

A Subsidiary of Harcourt Brace Jovanovich, Publishers
New York • London • Toronto • Sydney • San Francisco
111 FIFTH AVENUE, NEW YORK, N.Y. 10003

NEW JOURNAL

Investigational New Drugs

The Journal of New Anticancer Agents

EDITOR: DANIEL D. VON HOFF, M.D. (Cancer Therapy and Research Center, 4450 Medical Drive, San Antonio, Texas 78229, U.S.A.)

ASSOCIATE EDITORS: JOHN G. KUHN, Pharm. D. and GARY M. CLARK, Ph.D.

EDITORIAL ADVISORY BOARD

David S. Alberts (Tucson, Arizona), James Arseneau (Rochester, New York), Laurence Baker (Detroit, Michigan), Sam Barranco (Galveston, Texas), Alfred A. Bartolucci (Birmingham, Alabama), Robert Benjamin (Houston, Texas), Jurgen Bier (Berlin, West Germany), Arthur Bogden (Worcester, Massachusetts), Gianni Bonadonna (Milan, Italy), Ernest C. Borden (Madison, Wisconsin), Edward Bradley (Boston, Massachusetts), James Casper (Milwaukee, Wisconsin), Bruce Chabner (Bethesda, Maryland), Charles A. Coltman, Jr. (San Antonio, Texas), Stanley Crooke (Philadelphia, Pennsylvania), J. Paul Davignon (Bethesda, Maryland), Robert T. Dorr (Tucson, Arizona), John Driscoll (Silver Springs, Maryland), Laurence Einhorn (Indianapolis, Indiana), Edward Elslager (Ann Arbor, Michigan), William E. Evans (Memphis, Tennessee), Emil J. Freireich (Houston, Texas), Mike Friedman (San Francisco, California), Richard Gams (Birmingham, Alabama), Anne Hamburger (Rockville, Maryland), Daniel D. Hoth (Bethesda, Maryland), Lawrence H. Hurley (Austin, Texas), Brian Issell (Syracuse, New York), Randall K. Johnson (Cambridge, Massachusetts), William A. Knight III (San Antonio, Texas), John S. Kovach (Rochester, Minnesota), Irwin Krakoff (Burlington, Vermont), Maxwell Layard (Palo Alto, California), Sewa S. Legha (Houston, Texas), Robert Livingston (Cleveland, Ohio), Louis Malspeis (Columbus, Ohio), Charles G. Moertel (Rochester, Minnesota), Tom Moon (Tucson, Arizona), Lee Roy Morgan (New Orleans, Louisiana), Franco Muggia (New York, New York), G. Nagel (Göttingen, West Germany), Gary Neil (Kalamazoo, Michigan), Makoto Ogawa (Tokyo, Japan), Fred Ostroy (Birmingham, Alabama), H. M. Pinedo (Amsterdam, The Netherlands), Charles Pratt (Memphis, Tennessee), Marcel Rozenzweig (Brussels, Belgium), Sydney Salmon (Tucson, Arizona), John F. Sandbach (Austin, Texas), Milan Slavik (Albuquerque, New Mexico), Larry A. Sternson (Laurence, Kansas), Dale Stringfellow (Kalamazoo, Michigan), Ian F. Tannock (Toronto, Canada), Manuel Valdivieso (Houston, Texas), Fred A. Valeriote (St. Louis, Missouri), John Venditti (Bethesda, Maryland), Teresa Vietti (St. Louis, Missouri), Thomas Williams (Research Triangle Park, North Carolina)

AIMS AND SCOPE

The development of new anticancer agents is one of the most active aspects of cancer research. *Investigational New Drugs: The Journal of New Anticancer Agents* provides a forum for the rapid dissemination of information on new anticancer agents which the medicinal chemist, toxicologist, pharmacist, pharmacologist, biostatistician and clinical oncologist may utilize for efficient communication and exchange of data. It is the goal of *Investigational New Drugs* to provide the fastest possible publication of new discoveries and results for the community of scientists developing anticancer agents.

Volume 1, 1983, will be published in four quarterly issues. Each issue will contain from six to eight articles dealing with anticancer drug development. Additional sections will also be devoted to status reports from cooperative oncology groups, and reports from the National Cancer Institute on the status of each new investigational agent. Other sections will be devoted to invited review articles and letters to the editor. The journal will also afford the opportunity to publish the proceedings of special workshops and symposia devoted to the development of new anticancer agents. All manuscripts will be peer reviewed by a distinguished group of advisory editors.

SUBSCRIPTION RATES

The subscription price for 1983, Volume 1 (4 issues) is: for institutions Dfl. 175.00/US\$ 70.00 plus Dfl. 25.00/US\$ 10.00 for postage and handling. For individuals Dfl. 100.00/US\$ 40.00 including postage and handling. For airmail delivery please add Dfl. 22.00/US\$ 8.80. The journal is shipped to the USA and Canada in bulk airfreight at no extra cost.

ISSN 0167-6997

Free sample copies are available on request.



MARTINUS NIJHOFF PUBLISHERS

P.O. Box 566, 2501 CN The Hague, The Netherlands
190 Old Derby St., Hingham, MA 02043, USA

This publication is available in microform.



University Microfilms International

Please send additional information for _____
(name of publication)

Name _____

Institution _____

Street _____

City _____

State _____ Zip _____

300 North Zeeb Road
Dept. P.R.
Ann Arbor, Mi. 48106
U.S.A.

30-32 Mortimer Street
Dept. P.R.
London W1N 7RA
England